Analysis of c-kit expression in small cell lung cancer: Prevalence and prognostic implications

Lung Cancer

Volumn 52, Issue 3, 2006, Pages 343-347

  Camps, Carlos ^a   Sirera, Rafael ^a   Bremnes, Roy M ^b   Garde, Javier ^a   Safont, María José ^a   Blasco, Ana ^a   Berrocal, Alfonso ^a   Sánchez, José Javier ^c   Calabuig, Consuelo ^a   Martorell, Miguel ^a  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

c kit; Molecular markers; Prevalence; Prognostic factors; Small cell lung cancer (SCLC)

Indexed keywords

ETOPOSIDE; GROWTH FACTOR RECEPTOR; PLATINUM; STEM CELL FACTOR RECEPTOR; TUMOR MARKER;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE DURATION; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; SMOKING; SURVIVAL TIME; TISSUE DISTRIBUTION;

EID: 33646384917     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.02.003     Document Type: Article

References (40)

1. Simon G.R., and Wagner H. Small cell lung cancer. Chest 123 (2003) 259S-271S
2. Chute J.P., Chen T., Feigal E., Simon R., and Johnson B.E. Twenty years of phase III trials for patients with extensive-stage small-cell lung cancer: perceptible progress. J Clin Oncol 17 (1999) 1794-1801
3. Krause D.S., and Van Etten R.A. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353 (2005) 172-187
4. Zsebo K.M., Williams D.A., Geissler E.N., Broudy V.C., Martin F.H., Atkins H.L., et al. Stem cell factor is encoded at the Sl locus of the mouse and is the ligand for the c-kit tyrosine kinase receptor. Cell 63 (1990) 213-224
5. Sattler M., and Salgia R. Targeting c-Kit mutations: basic science to novel therapies. Leuk Res 28 Suppl 1 (2004) S11-S20
6. Broxmeyer H.E., Cooper S., Lu L., Hangoc G., Anderson D., Cosman D., et al. Effect of murine mast cell growth factor (c-kit proto-oncogene ligand) on colony formation by human marrow hematopoietic progenitor cells. Blood 77 (1991) 2142-2149
7. Halaban R. Growth factors and tyrosine protein kinases in normal and malignant melanocytes. Cancer Metastasis Rev 10 (1991) 129-140
8. Matsui Y., Zsebo K.M., and Hogan B.L. Embryonic expression of a haematopoietic growth factor encoded by the Sl locus and the ligand for c-kit. Nature 347 (1990) 667-669
9. Natali P.G., Berlingieri M.T., Nicotra M.R., Fusco A., Santoro E., Bigotti A., et al. Transformation of thyroid epithelium is associated with loss of c-kit receptor. Cancer Res 55 (1995) 1787-1791
10. Reilly J.T. Receptor tyrosine kinases in normal and malignant haematopoiesis. Blood Rev 17 (2003) 241-248
11. Ward S.M., Burns A.J., Torihashi S., and Sanders K.M. Mutation of the proto-oncogene c-kit blocks development of interstitial cells and electrical rhythmicity in murine intestine. J Physiol 480 Pt 1 (1994) 91-97
12. Fletcher C.D., Berman J.J., Corless C., Gorstein F., Lasota J., Longley B.J., et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 33 (2002) 459-465
13. Nagata H., Worobec A.S., Oh C.K., Chowdhury B.A., Tannenbaum S., Suzuki Y., et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci USA 92 (1995) 10560-10564
14. Hibi K., Takahashi T., Sekido Y., Ueda R., Hida T., Ariyoshi Y., et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 6 (1991) 2291-2296
15. Krystal G.W., Hines S.J., and Organ C.P. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 56 (1996) 370-376
16. Strohmeyer T., Reese D., Press M., Ackermann R., Hartmann M., and Slamon D. Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue. J Urol 153 (1995) 511-515
17. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
18. Lonardo F., Pass H.I., and Lucas D.R. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 11 (2003) 51-55
19. Sekido Y., Obata Y., Ueda R., Hida T., Suyama M., Shimokata K., et al. Preferential expression of c-kit protooncogene transcripts in small cell lung cancer. Cancer Res 51 (1991) 2416-2419
20. Krystal G.W., Honsawek S., Kiewlich D., Liang C., Vasile S., Sun L., et al. Indolinone tyrosine kinase inhibitors block Kit activation and growth of small cell lung cancer cells. Cancer Res 61 (2001) 3660-3668
21. Heinrich M.C., Blanke C.D., Druker B.J., and Corless C.L. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 20 (2002) 1692-1703
22. Savage D.G., and Antman K.H. Imatinib mesylate-a new oral targeted therapy. N Engl J Med 346 (2002) 683-693
23. Geissler E.N., Ryan M.A., and Housman D.E. The dominant-white spotting (W) locus of the mouse encodes the c-kit proto-oncogene. Cell 55 (1988) 185-192
24. Heinrich M.C. Is KIT an important therapeutic target in small cell lung cancer?. Clin Cancer Res 9 (2003) 5825-5828
25. Wolff N.C., Randle D.E., Egorin M.J., Minna J.D., and Ilaria Jr. R.L. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer. Clin Cancer Res 10 (2004) 3528-3534
26. Araki K., Ishii G., Yokose T., Nagai K., Funai K., Kodama K., et al. Frequent overexpression of the c-kit protein in large cell neuroendocrine carcinoma of the lung. Lung Cancer 40 (2003) 173-180
27. Blackhall F.H., Pintilie M., Michael M., Leighl N., Feld R., Tsao M.S., et al. Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancer. Clin Cancer Res 9 (2003) 2241-2247
28. Boldrini L., Ursino S., Gisfredi S., Faviana P., Donati V., Camacci T., et al. Expression and mutational status of c-kit in small-cell lung cancer: prognostic relevance. Clin Cancer Res 10 (2004) 4101-4108
29. Casali C., Stefani A., Rossi G., Migaldi M., Bettelli S., Parise A., et al. The prognostic role of c-kit protein expression in resected large cell neuroendocrine carcinoma of the lung. Ann Thorac Surg 77 (2004) 247-252
30. Goldstein N.S. C-kit expression in small cell lung carcinomas. Hum Pathol 34 (2003) 827
31. Micke P., Basrai M., Faldum A., Bittinger F., Ronnstrand L., Blaukat A., et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 9 (2003) 188-194
32. Naeem M., Dahiya M., Clark J.I., Creech S.D., and Alkan S. Analysis of c-kit protein expression in small-cell lung carcinoma and its implication for prognosis. Hum Pathol 33 (2002) 1182-1187
33. Potti A., Moazzam N., Ramar K., Hanekom D.S., Kargas S., and Koch M. CD117 (c-KIT) overexpression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 14 (2003) 894-897
34. Rohr U.P., Rehfeld N., Pflugfelder L., Geddert H., Muller W., Steidl U., et al. Expression of the tyrosine kinase c-kit is an independent prognostic factor in patients with small cell lung cancer. Int J Cancer 111 (2004) 259-263
35. Rossi G., Cavazza A., Marchioni A., Migaldi M., Bavieri M., Facciolongo N., et al. Kit expression in small cell carcinomas of the lung: effects of chemotherapy. Mod Pathol 16 (2003) 1041-1047
36. Potti A., Ganti A.K., Tuchman S.A., Sholes K., Langness E., Koka V., et al. HER-2/neu and CD117 (c-kit) overexpression in patients with pesticide exposure and extensive stage small cell lung carcinoma (ESSCLC). J Carcinog 4 (2005) 8
37. Krystal G.W., Honsawek S., Litz J., and Buchdunger E. The selective tyrosine kinase inhibitor STI571 inhibits small cell lung cancer growth. Clin Cancer Res 6 (2000) 3319-3326
38. Burger H., den Bakker M.A., Stoter G., Verweij J., and Nooter K. Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens. Eur J Cancer 39 (2003) 793-799
39. Mojica W.D., Saxena R., Starostik P., and Cheney R.T. CD117+ small cell lung cancer lacks the asp 816 → val point mutation in exon 17. Histopathology 47 (2005) 517-522
40. Tamborini E., Bonadiman L., Negri T., Greco A., Staurengo S., Bidoli P., et al. Detection of overexpressed and phosphorylated wild-type kit receptor in surgical specimens of small cell lung cancer. Clin Cancer Res 10 (2004) 8214-8219